Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table At a glance Prototype drug / retatrutide (LY3437943) Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor agonism Phase 2 weight loss (48 wk) / 24.2% mean body weight reduction vs 2.1% placebo Primary metabolic targets / obesity, MASLD/MASH, T2D, dyslipidemia Gastric emptying effect / marked slowing, peak drug interaction risk 1 to 4 h post-dose Oral drug most affected / warfarin, oral contraceptives, levothyroxine, cyclosporine Hypoglycemia risk / low monotherapy
Cost: Semaglutide can be expensive, especially if not covered by insurance
353,354 For instance, protecting Schwann cells from glucose-induced toxicity improves nerve function and promotes remyelination in experimental models
The choice between GLP-1 medications should involve cardiac considerations alongside efficacy and tolerability
Competitive landscape: Global and domestic players India is becoming a focal market for competition between global pharmaceutical leaders